THE IMMUNE RESPONSE TO CANCER AS A NEW DECISION-MAKING TOOL
HalioDx designs and develops diagnostic tests in oncology utilizing the immune contexture of cancers; a concept pioneered by Jérôme Galon and his team at the Integrative Cancer Immunology Laboratory (Centre de Recherche des Cordeliers, Paris). By precisely measuring the immune reaction in and around the tumor, the HalioDx ambition is to change the paradigm of cancer diagnosis.
Closely derived from the immune contexture concept, the Immunoscore® assay analyzes the type, location, and density of immune infiltrates in colorectal tumors providing unique prognostic information that outperforms the UICC – TNM classification of colorectal tumors. Because Immunoscore® represents the most relevant immune biomarker in the assessment of the natural evolution of tumors, its potential to predict response to immunomodulatory treatments is promising.
The former management team from Ipsogen SA, which then became Qiagen Marseille in 2013, created HalioDx. Leveraging on the success of Ipsogen, recognized as the leader of the molecular diagnostic of leukemia, the team intends to make HalioDx a unique Immuno-Oncology company providing breakthrough diagnostic innovations to clinicians and patients.
An innovative start-up with strong leadership and expertise in cancer diagnostics, HalioDx has an experienced team of 75 employees and compliant facilities to develop, manufacture, deliver and market in vitro diagnostic products and services in Immuno-Oncology. HalioDx is one of the founding members of Immunopôle Marseille, a European cluster dedicated to fundamental and applied immunology.
Immunoscore® Colon is the first HalioDx diagnostic test. With unrivalled prognostic power, this test significantly improves the classification of stage II Colon Cancer, which in turn, helps to identify patients at a higher risk for recurrence. More